MYRIAD GENETICS INC (MYGN) Stock News

Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mentions: GSK

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via...

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after...

What Analysts Are Saying About Myriad Genetics Stock

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via ultra-sensitive MRD

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators...

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators

UnitedHealth downgraded, Home Depot upgraded: Wall Street's top analyst calls

UnitedHealth downgraded, Home Depot upgraded: Wall Street's top analyst calls

Mentions: UNH HD AZO HSBC ...

This UnitedHealth Group Analyst Turns Bearish; Here Are Top 3 Downgrades For Wednesday

Mentions: PNNT UNH

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Correction: Time of BofA Conference...

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Correction: Time of BofA Conference

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Paul Singer’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other stock picks with huge upside potential. Paul Singer founded Elliott Investment Management in 1977 in New York. It is one of the […]

Mentions: BMRN UNP POOL

Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround

Myriad (MYGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Myriad Genetics Shares Tank 41% On Analyst Downgrades, Weaker Guidance: Yet Retail Investors Remain Bullish

Analysts, including those from Wells Fargo, UBS, Raymond James, and Craig-Hallum, slashed their price targets and expressed concerns over the company's growth and execution challenges.

Mentions: WFC UBS RJF

Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk...

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk

MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook

Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.

Mentions: BSX ANGO ITGR

Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 40% and 2.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: WVE